Appeals Court Reverses Patent Ruling on Schering's Temodar

摘要

A federal appeals court has reversed a lower court's ruling in a patent dispute over the brain cancer treatment Temodar, strengthening Schering's protection on the drug.rnIn a ruling issued Tuesday by a three-judge panel of the U.S. Court of Appeals for the Federal Circuit, the court reversed an earlier ruling from a Delaware federal court and found that Schering's '291 patent on Temodar (temozolomide) was not invalid for inequitable conduct or delays in having the patent issued by the PTO.